CAS: 13345-51-2; Prostaglandinb1

该化合物是一种生物活性脂质化合物,在身体内各种生理过程中起着重要作用,是来自芳香酸的plastlandin家族的成员,参与调节炎症,调节血液流动和影响免疫反应.Prostaglandin B(1) 具有独特的结构特征,包括环球环和多种功能组,有助于其生物活动.它以血管效应著称,它有助于调节血压,促进血液流向组织.此外,Prostaglandin B(1) 已经研究其潜在的治疗用途,包括其在胃肠保护中的作用及其对生殖健康的影响.由于其复杂性质和参与各种生物化学途径,Prostalandin B(1) 有兴趣进行药理学和医学研究,特别是在炎症和心血管健康方面.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2003050305-A1
    优先权日:2000-05-22
    标题:Thromboxane inhibitors, compositions and methods of use
    发明人:TEJADA INIGO SAENZ DE
    摘要:The present invention describes methods for treating or preventing sexual dysfunctions in males and females, and for enhancing sexual responses in males and females by administering a therapeutically effective amount of at least one thromboxane inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The male or female may preferably be diabetic. The present invention also provides novel compositions comprising at least one thromboxane inhibitor, and, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and, optionally, at least one therapeutic agent, such as, vasoactive agents, nonsteroidal antiinflanmmatory compounds (NSAIDs), selective cyclooxygenase-2 (COX-2) inhibitors, anticoagulants, angiotensin converting enzymes (ACE) inhibitors, angiotensin II receptor antagonists, renin inhibitors, and mixtures thereof. The present invention also provides methods for treating or preventing ischemic heart disorders, myocardial infarction, angina pectoris, stroke, migraine, cerebral hemorrhage, cardiac fatalities, transient ischaemic attacks, complications following organ transplants, coronary artery bypasses, angioplasty, endarterectomy, atherosclerosis, pulmonary embolism, bronchial asthma, bronchitis, pneumonia, circulatory shock of various organs, nephritis, graft rejection, cancerous metastases, pregnancy-induced hypertension, preeclampsia, eclampsia, thrombotic and thromboembolic disorders, intrauterine growth, gastrointestinal disorders, renal diseases and disorders, disorders resulting from elevated uric acid levels and dysmenorrhea, and for inhibiting platelet aggregation or platelet adhesion or relaxing smooth muscles.

    专利号:US-5905091-A
    优先权日:1996-07-03
    标 题 :Enhancement of skin pigmentation by prostaglandins
    发明人:FULLER BRYAN B
    权利人:UNIV OKLAHOMA
    摘要:A composition comprising a carrier and prostaglandin effective in stimulating synthesis of melanin in a human melanocyte thereby enhancing pigmentation of the human skin and optionally comprising a lysosomotropic agent, a phosphodiesterase inhibitor, and/or methylxanthines, and a method of use of the composition. Use of this composition promotes tanning of the human skin and increases photoprotection from ultraviolet radiation.

    专利号:US-7772278-B2
    优先权日:1999-03-01
    标 题:Nitrosated and nitrosylated prostaglandins, compositions and methods of use
    发明人:GARVEY DAVID S; GASTON RICKY D; LETTS L GORDON; DE TEJADA INIGO SAENZ; TAM SANG WILLIAM; WORCEL MANUEL
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and/or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E 1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.

    专利号:US-2004110228-A1
    优先权日:2002-04-01
    标 题:Combinatorial organic synthesis of unique biologically active compounds
    发明人:MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
    摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

    专利号:US-4833271-A
    优先权日:1985-08-23
    标 题 :Structurally defined oligomers and preparation thereof for the protection of oxidative phosphorylation and which exhibit ionophoretic activity
    发明人:NELSON GEORGE L
    权利人:NELSON GEORGE L
    摘要:Structurally-defined, low molecular weight oligomers and preparation thereof which are active in the protection of oxidative physphorylation of mitochondria and exhibit ionophoretic activity. Said structurally defined low molecular weight oligomers are synthesized using a modified 15-dehydro PGB1 such as 16,16-dimethyl-15-dehydro prostaglandin B1 as a precursor to obtain oligomeric mixtures which are structurally defined and active in the protection of oxidative phosphorylation and exhibit ionophoretic activity. Synthesis of modified 15-dehydro-PGB1; 16,16-dimethyl-15-dehydro-prostagalandin B1; is also described.

    专利号:US-5605929-A
    优先权日:1992-05-27
    标题:Methods and compositions for inhibiting 5α-reductase activity
    发明人:LIAO SHUTSUNG; LIANG TEHMING
    权利人:ARCH DEV CORP
    摘要:Disclosed are a novel class of antiandrogenic compounds including saturated and unsaturated fatty acids, catechin gallates, their derivatives, and synthetic analogs, their method of synthesis, and their use in treating disorders associated with androgenic activities. Also disclosed is the use of known compounds not previously known for their antiandrogenic activity in treating disorders related to androgenic activities and cancers.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Yeo J, Lee YH, Jeon SM, Jung UJ, Lee MK, Jung YM, Choi MS. Supplementation of a novel microbial biopolymer, PGB1, from new Enterobacter sp. BL-2 delays the deterioration of type 2 diabetic mice. J Microbiol Biotechnol. 2007 Dec;17(12):1983-90. 11(1):19-29. doi: 10.1038/nmat3191. Erratum in: Nat Mater. 2012 Feb;11(2):172. 43(2):63-70. doi: 10.1016/0952-3278(91)90173-3. 92(1):257-66. doi: 10.1529/biophysj.106.088682. Epub 2006 Oct 13. Erratum in: Biophys J. 2009 May 6;96(9):3886.
    5: DeTitta GT, Langs DA, Edmonds JW. Prostaglandins PGA1 and PGB1. Crystallographic studies of the conformational requirements for 15-hydroxyprostaglandin dehydrogenase activity. Biochemistry. 1979 Jul 24;18(15):3387-91. doi: 10.1021/bi00582a027.
    135:141-148. doi: 10.1016/j.plaphy.2018.11.036. Epub 2018 Nov 29. 123(9):1920-1930. doi: 10.1021/acs.jpcb.8b10774. Epub 2019 Feb 26.

    合成参考文献


    参考文献:10.1016/s0026-895x(25)09373-3
    摘要:Itoh S, Lu R, Bao Y, Morrow JD, Roberts LJ, Schuster VL. Structural determinants of substrates for the prostaglandin transporter PGT. Molecular Pharmacology. 1996 Oct;50(4):736–42. doi: 10.1016/s0026-895x(25)09373-3.
    参考文献:10.1038/s41467-021-24482-1
    摘要:Wu P, Chen D, Ding W, Wu P, Hou H, Bai Y, Zhou Y, Li K, Xiang S, Liu P, Ju J, Guo E, Liu J, Yang B, Fan J, He L, Sun Z, Feng L, Wang J, Wu T, Wang H, Cheng J, Xing H, Meng Y, Li Y, Zhang Y, Luo H, Xie G, Lan X, Tao Y, Li J, Yuan H, Huang K, Sun W, Qian X, Li Z, Huang M, Ding P, Wang H, Qiu J, Wang F, Wang S, Zhu J, Ding X, Chai C, Liang L, Wang X, Luo L, Sun Y, Yang Y, Zhuang Z, Li T, Tian L, Zhang S, Zhu L, Chang A, Chen L, Wu Y, Ma X, Chen F, Ren Y, Xu X, Liu S, Wang J, Yang H, Wang L, Sun C, Ma D, Jin X, Chen G. The trans-omics landscape of COVID-19. Nature Communications. 2021 Jul 27;12(1):4543. doi: 10.1038/s41467-021-24482-1.
    参考文献:10.1073/pnas.94.2.746
    摘要:Rossi A, Elia G, Santoro M . Inhibition of nuclear factor κB by prostaglandin A1: An effect associated with heat shock transcription factor activation. Proc. Natl. Acad. Sci. U.S.A. 1997 Jan 21;94(2):746–50. doi: 10.1073/pnas.94.2.746.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知